Taivex Therapeutics Corporation will attend Bio Asia-Taiwan 2024
Taivex is dedicated to the development of novel cancer therapeutics and possesses multiple First-in-Class/Best-in-Class anticancer targeted drugs. Taivex will attend the Bio Asia-Taiwan 2024, BIO One-on-One PartneringTM to seek for potential collaboration partner for licensing out or co-development opportunities. T-1101 is a First-in-Class oral capsule formulation. The enrollment of study subject of T-1101 Phase I …
Taivex Therapeutics Corporation will attend Bio Asia-Taiwan 2024 Read More »